'HR Excellence in Research' logo awarded to institutions actively implementing the European Charter and Code for Researchers.
Please note that the job is no longer active!
Investigation of MRD has proven to be a valuable tool in patients with acute leukemias for predicting impending relapses and improving patient stratification. The main aim of MRD studies is to allow the possibility to establish tailored therapies based on the burden of residual leukemic cells, which is proved to be a major risk factor for relapse. Wt1 is an important molecular of MRD in patient with AML with intermediate risk. The present study is focused on the evaluation of MRD in a prospective study of a cohort of patients affected by AML receiving an homogeneous treatment and fully characterized by a cytogenetic and molecular point of view. In addition the prognostic significance of WT1 mutations will be established and correlated with the presence of additional lesions and finally to the chemotherapy sensibility and final outcome.
Please note that the full description may be available in the national language since some job boards have their own publication policy. Thank you for your understanding!
The call, the requirements and how to apply are available at the following address: https://www.serviziweb.unito.it/albo_ateneo/
To better plan and organise their stay in a foreign European country, researchers and their families can also benefit of the free and personalised assistance offered by the EURAXESS Services Centres, a network of more than 200 centres located in 40 different European countries.